US Patent
US11938136 — Compositions for treating spinal muscular atrophy
Formulation · Assigned to Hoffmann La Roche Inc · Expires 2036-11-08 · 10y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects pharmaceutical compositions containing a compound of formula (I) and its pharmaceutically acceptable salts, used as medicaments.
USPTO Abstract
The present invention provides pharmaceutical compositions comprising a compound of formula (I) wherein A, R 1 , R 2 and R 3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the pharmaceutical compositions comprising a compound of formula (I) and their use as medicaments.
Drugs covered by this patent
- Evrysdi (RISDIPLAM) · Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.